We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data
Read MoreHide Full Article
Key Takeaways
CTMX shares jumped 44% after strong phase I expansion data for Varseta-M in late-line metastatic CRC.
CTMX reported response rates rising from 6% to 32% across dose levels, with disease control reaching 88%.
CTMX plans FDA talks to align on a registrational CRC study and plans new studies with Avastin combos.
Shares of CytomX Therapeutics (CTMX - Free Report) soared 44.2% on Monday after the company reported positive phase I expansion data for its EpCAM-targeting PROBODY ADC, varsetatug masetecan (Varseta-M), in late-line metastatic colorectal cancer (CRC) from the ongoing CTMX-2051-101 study.
Patients in the study were heavily pretreated, having received a median of three prior metastatic therapies, and 96% had prior irinotecan exposure. Out of the total enrolled population, 76% had liver metastases and 71% carried KRAS mutations. Although patients were not selected based on EpCAM expression, all evaluable tumor biopsies showed high EpCAM levels.
CTMX’s Phase I Colorectal Cancer Study Data in Detail
In the phase I expansion portion of the CTMX-2051-101 study, CytomX Therapeutics reported encouraging efficacy signals for Varseta-M in patients with heavily pretreated metastatic CRC. As of Jan. 16, 2026, data cutoff, 56 patients across the 7.2 mg/kg, 8.6 mg/kg and 10 mg/kg dose cohorts were evaluable for efficacy, out of the enrolled 60, with a median follow-up of about eight months. The therapy demonstrated increasing activity at higher dose levels, with confirmed overall response rates of 6% at 7.2 mg/kg, 20% at 8.6 mg/kg and 32% at 10 mg/kg.
Progression-free survival also improved with dose escalation. Median progression-free survival was 5.5 months at 7.2 mg/kg, rising to 6.8 months at 8.6 mg/kg and 7.1 months at the 10 mg/kg dose. Disease control rates remained high across cohorts, reaching 88% overall across the expansion population, suggesting the therapy was able to stabilize disease in a large proportion of treated patients.
In the past six months, CTMX shares have skyrocketed 230.9% compared with the industry’s 14.5% growth.
Image Source: Zacks Investment Research
Based on these results, the 8.6 mg/kg and 10 mg/kg regimens have been prioritized for further evaluation as CytomX Therapeutics works to identify a potential dose or doses for a registrational study. Dose-optimization efforts using adjusted ideal body weight dosing and updated prophylaxis for adverse-event management are ongoing.
Varseta-M demonstrated a generally manageable safety profile in the phase I study, consistent with interim clinical data reported last year, with most treatment-related adverse events reported as mild to moderate in severity. One treatment-related severe acute kidney injury occurred earlier in the study in a patient with a complex medical history, with no additional severe events observed as of the January 2026 data cutoff.
CTMX’s Next Steps in the Development of Varseta-M
CytomX Therapeutics plans to continue advancing Varseta-M through clinical development, with additional efficacy and safety data from the ongoing phase I advanced CRC study expected to be presented at medical meetings in 2026. The company also intends to engage with the FDA during the year to discuss a potential registrational study design evaluating Varseta-M monotherapy in advanced CRC. In this setting, patients currently have limited treatment options.
In parallel, CytomX Therapeutics is exploring combination strategies to broaden the therapy’s clinical potential. A phase I study evaluating Varseta-M in combination with Roche’s Avastin (bevacizumab) in CRC has already been initiated. A phase Ib/II study combining Varseta-M with Avastin and chemotherapy is also expected to begin by the end of 2026. The company is also planning to launch phase I expansion cohorts in additional EpCAM-expressing cancers in the second half of 2026.
Over the past 60 days, estimates for Castle Biosciences’ 2026 loss per share have narrowed from $1.11 to $1.06. CSTL shares have gained 10.1% over the past six months.
Castle Biosciences’ earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 34.69%.
Over the past 60 days, estimates for Catalyst Pharmaceuticals’ 2026 earnings per share have risen from $2.55 to $2.82. CPRX shares have gained 14.2% over the past six months.
Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.
Over the past 60 days, estimates for ALX Oncology Holdings’ 2026 loss per share have narrowed from $1.21 to 90 cents. ALXO shares have surged 90.8% over the past six months.
ALX Oncology Holdings’ earnings missed estimates in each of the trailing four quarters, with the average negative surprise being 12.82%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data
Key Takeaways
Shares of CytomX Therapeutics (CTMX - Free Report) soared 44.2% on Monday after the company reported positive phase I expansion data for its EpCAM-targeting PROBODY ADC, varsetatug masetecan (Varseta-M), in late-line metastatic colorectal cancer (CRC) from the ongoing CTMX-2051-101 study.
Patients in the study were heavily pretreated, having received a median of three prior metastatic therapies, and 96% had prior irinotecan exposure. Out of the total enrolled population, 76% had liver metastases and 71% carried KRAS mutations. Although patients were not selected based on EpCAM expression, all evaluable tumor biopsies showed high EpCAM levels.
CTMX’s Phase I Colorectal Cancer Study Data in Detail
In the phase I expansion portion of the CTMX-2051-101 study, CytomX Therapeutics reported encouraging efficacy signals for Varseta-M in patients with heavily pretreated metastatic CRC. As of Jan. 16, 2026, data cutoff, 56 patients across the 7.2 mg/kg, 8.6 mg/kg and 10 mg/kg dose cohorts were evaluable for efficacy, out of the enrolled 60, with a median follow-up of about eight months. The therapy demonstrated increasing activity at higher dose levels, with confirmed overall response rates of 6% at 7.2 mg/kg, 20% at 8.6 mg/kg and 32% at 10 mg/kg.
Progression-free survival also improved with dose escalation. Median progression-free survival was 5.5 months at 7.2 mg/kg, rising to 6.8 months at 8.6 mg/kg and 7.1 months at the 10 mg/kg dose. Disease control rates remained high across cohorts, reaching 88% overall across the expansion population, suggesting the therapy was able to stabilize disease in a large proportion of treated patients.
In the past six months, CTMX shares have skyrocketed 230.9% compared with the industry’s 14.5% growth.
Image Source: Zacks Investment Research
Based on these results, the 8.6 mg/kg and 10 mg/kg regimens have been prioritized for further evaluation as CytomX Therapeutics works to identify a potential dose or doses for a registrational study. Dose-optimization efforts using adjusted ideal body weight dosing and updated prophylaxis for adverse-event management are ongoing.
Varseta-M demonstrated a generally manageable safety profile in the phase I study, consistent with interim clinical data reported last year, with most treatment-related adverse events reported as mild to moderate in severity. One treatment-related severe acute kidney injury occurred earlier in the study in a patient with a complex medical history, with no additional severe events observed as of the January 2026 data cutoff.
CTMX’s Next Steps in the Development of Varseta-M
CytomX Therapeutics plans to continue advancing Varseta-M through clinical development, with additional efficacy and safety data from the ongoing phase I advanced CRC study expected to be presented at medical meetings in 2026. The company also intends to engage with the FDA during the year to discuss a potential registrational study design evaluating Varseta-M monotherapy in advanced CRC. In this setting, patients currently have limited treatment options.
In parallel, CytomX Therapeutics is exploring combination strategies to broaden the therapy’s clinical potential. A phase I study evaluating Varseta-M in combination with Roche’s Avastin (bevacizumab) in CRC has already been initiated. A phase Ib/II study combining Varseta-M with Avastin and chemotherapy is also expected to begin by the end of 2026. The company is also planning to launch phase I expansion cohorts in additional EpCAM-expressing cancers in the second half of 2026.
CytomX Therapeutics, Inc. Price and Consensus
CytomX Therapeutics, Inc. price-consensus-chart | CytomX Therapeutics, Inc. Quote
CTMX’s Zacks Rank & Stocks to Consider
CytomX Therapeutics currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Castle Biosciences (CSTL - Free Report) , Catalyst Pharmaceuticals (CPRX - Free Report) and ALX Oncology Holdings (ALXO - Free Report) . While USNA and CPRX sport a Zacks Rank #1 (Strong Buy) each, ALXO carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Castle Biosciences’ 2026 loss per share have narrowed from $1.11 to $1.06. CSTL shares have gained 10.1% over the past six months.
Castle Biosciences’ earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 34.69%.
Over the past 60 days, estimates for Catalyst Pharmaceuticals’ 2026 earnings per share have risen from $2.55 to $2.82. CPRX shares have gained 14.2% over the past six months.
Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.
Over the past 60 days, estimates for ALX Oncology Holdings’ 2026 loss per share have narrowed from $1.21 to 90 cents. ALXO shares have surged 90.8% over the past six months.
ALX Oncology Holdings’ earnings missed estimates in each of the trailing four quarters, with the average negative surprise being 12.82%.